Capsida Suspends Gene Therapy Trial After First Patient Death on September 12, 2025 CAP-002 Capsida Biotherapeutics Clinical Trial Suspension Encephalopathies gene therapy Patient Death STXBP1 gene United States Food and Drug Administration +
CytomX Continues Phase I ADC Study After Patient Death on August 14, 2025 ADC Clinical Trials Colorectal Carcinoma CX-2051 CytomX Kidney Failure, Acute Patient Death Phase I Safety therapeutic autologous dendritic cells United States Food and Drug Administration +
Allogene Reports Patient Death Linked to ALLO-647 Conditioning Antibody in CAR-T Trial on August 04, 2025 Adenovirus Infections Allogene ALPHA3 trial Anti-CD52 Monoclonal Antibody ALLO-647 CAR-T Liver Failure Lymphodepletion Therapy Monoclonal Antibodies Patient Death +
FDA Investigates Elevidys Death; Sarepta and Roche Deny Link to Gene Therapy on July 28, 2025 Brazil Elevidys gene therapy Market Muscular Dystrophy, Duchenne Patient Death Roche (company) Safety Suspensions United States Food and Drug Administration +
Sarepta Reports Third Patient Death in Gene Therapy Studies for Limb-Girdle Muscular Dystrophy on July 18, 2025 AAVS1 gene Elevidys gene therapy Liver Failure, Acute Muscular Dystrophies, Limb-Girdle Patient Death Safety Study on Hold United States Food and Drug Administration vector +
Second Patient Dies After Receiving Sarepta's Elevidys Gene Therapy for DMD on June 17, 2025 AAV-based gene therapy Elevidys gene therapy Liver Failure, Acute Muscular Dystrophy, Duchenne Patient Death risk mitigation Unable to walk (finding) United States Food and Drug Administration +
Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold on May 27, 2025 acute systemic infection Adverse event Capillary Leak Syndrome gene therapy Glycogen Storage Disease Type IIb Patient Death Rocket RP-A501 Study on Hold United States Food and Drug Administration +